Updated
Original VAYEMA symptom and impact self-check – not a validated scale
Z-drug and sleep-medicine concerns
Answer the symptom statements below to see which experiences and areas of daily life you report as most affected. These are original VAYEMA questions, not a validated diagnostic scale. No clinical severity or probability score is calculated.
Answers are processed only in this page by this assessment. They are not submitted, monitored or automatically saved. No name, email or account is required. Use a private device and clear your answers when finished.
For adults aged 18 and over. This self-check cannot diagnose or rule out a condition. Concerns about a child require an age-appropriate professional assessment.
Thinking about the past four weeks, how well does each statement describe your experience?
Additional context – not included in any questionnaire score
These are original VAYEMA questions, not a diagnostic instrument or a validated severity scale. They summarise the experiences you select and do not predict a diagnosis or future harm. Background condition information; this source does not endorse this self-check.
What the medication assessment should answer
The review asks whether the medicine is still helping, what risks are present and what support is needed for any change. Physical dependence can arise during prescribed use and is not the same as a substance-use disorder. An assessment should explore actual use and any loss of control separately. The aim is an appropriate recommendation, not a judgement about whether accepting a sleep prescription was a mistake.
NICE guidance supports shared decisions about continuing, reducing or stopping treatment. You can explain a wish to stop, uncertainty about dependence or a problem with side effects. The outcome should address that concern and the original insomnia together. Our understanding guide provides background, but you do not need a diagnostic label before requesting a review.
Identify the actual medicine and how it has been taken
Bring the name, formulation, prescribed instructions and the pattern you actually follow. Different Z-drugs are not interchangeable, and modified formulations can matter to a clinical decision. Include earlier switches, prescriptions from other services and any non-prescribed sleep products. The NHS zopiclone information is an example of medicine-specific advice; it should not be treated as instructions for every sleeping medicine.
An approximate history is acceptable when details are uncertain. Pharmacy or earlier clinical records may help, but they should not become a barrier to asking for support. Do not convert doses, change brands or split a product according to an online guide while preparing. Explain any use that differs from the prescription without trying to make the account look better. Accurate information allows a clinician to plan more safely and respectfully.
Describe the sleep problem before and during treatment
The clinician may ask when insomnia began, what was happening at the time and which parts of sleep are difficult now. Trouble falling asleep, repeated waking, early waking and daytime impairment may raise different questions. A medicine can change the experience without explaining its cause. Relevant medical, psychological and practical circumstances should be considered rather than assuming all poor sleep is dependence-related.
A short account of nights and days can be more useful than an exact average. Mention work schedules, caring responsibilities, pain, breathing symptoms and any earlier sleep evaluation. The insomnia assessment guide explains how a diary can help, but it is optional. You do not need a wearable or a perfect record before a professional can begin understanding the problem.
Previous reductions can provide important information
Describe what changed, the timing of symptoms and whether they felt different from the original sleep problem. A missed dose, sudden stop and supported reduction are not necessarily comparable experiences. Withdrawal and the return of insomnia can overlap. The NICE evidence discussion recognises that new or changed symptoms need interpretation rather than an automatic conclusion.
Do not deliberately skip medication to recreate symptoms for the appointment. An honest account of earlier difficulties is sufficient. Include any severe confusion, seizure, hospital visit or other significant complication. A difficult attempt does not prove that change is impossible or that you failed. It helps the clinician consider the appropriate setting, pace and support, including whether another health concern needs investigation.
Ask about daytime functioning and adverse effects
Sleep treatment should be assessed by more than whether you fall asleep. Morning alertness, memory, balance, driving and daily functioning can also matter. Tell the clinician about difficulties even when you are unsure of their cause. They may reflect the medicine, poor sleep, another condition or a combination. The assessment should explore the pattern rather than assume one explanation based on a website list.
The FDA Z-drug information highlights possible next-day impairment. Avoid driving or hazardous activities when impaired and seek appropriate medical advice about concerning effects. Serious sedation, abnormal breathing or inability to wake normally needs urgent care. Such symptoms should not be saved for a routine appointment simply because the medicine was prescribed or taken previously without an obvious problem.
Unusual sleep behaviours require direct clinical contact
Activities carried out while not fully awake, sometimes without later memory, can be serious adverse reactions. For zolpidem, eszopiclone and zaleplon, the FDA warning instructs patients to stop the medicine and contact a healthcare professional immediately after a complex sleep behaviour. Do not use the worksheet to decide whether an event was serious enough to follow that advice.
A person with possible dependence also needs prompt professional help with safe discontinuation. This is a specific adverse-event situation, different from an ordinary planned taper. Follow the instructions for the actual product and obtain emergency help for injury or immediate danger. A brief note about what happened and who witnessed it may assist the receiving clinician later, but documenting the event should not delay direct advice.
Review other medicines, substances and medical circumstances
Include medicines for anxiety, pain, sleep or other conditions, pharmacy products, alcohol and non-prescribed substances. Products used on different occasions can still be relevant to the assessment. Tell the clinician about breathing disorders, falls, pregnancy or other significant health changes. The recommendation should consider these factors together rather than review the sleep medicine in isolation.
Do not add a sedative or stop several treatments independently to simplify the situation. A coordinated review may be needed when different clinicians prescribe. The MHRA’s current communication emphasises clear information about Z-drug dependence and withdrawal risks. Ask which professional leads the plan and how relevant records will be shared, so you are not left to reconcile incompatible instructions yourself.
A self-test cannot determine the safest withdrawal plan
Questionnaires can sometimes support clinical assessment, but a numerical result cannot choose a medicine, dose reduction or care setting. It cannot observe symptoms or account for every interaction and previous complication. An original worksheet is not made clinically validated by displaying a percentage or a severity colour. These prompts deliberately provide no diagnostic or withdrawal-risk score.
You can describe your concerns without a form or bring a limited set of notes. The professional should explain what the history suggests and what remains uncertain. A lower amount of medication does not automatically mean that abrupt stopping is safe, while a long history does not establish that hospital care is always necessary. Both conclusions require individual clinical judgement rather than an online threshold.
Discuss insomnia treatment and the next review together
The plan should explain how the original sleep problem will be supported during any medication change. Structured insomnia treatment may be useful; NHLBI describes CBT-I as a usual first treatment for long-term insomnia. It differs from a general relaxation session or a generic list of bedtime rules. Medical or specialist sleep assessment may also be appropriate.
The Z-drug treatment guide explains supervised review, while the insomnia guide covers related options. Ask how the professionals will coordinate and what to do if symptoms worsen before the next appointment. A clear review point and contact plan are more useful than a vague promise to provide support throughout an unspecified process.
Prepare only what helps, and keep information private
The worksheet does not send answers, generate clinical alerts or create a patient record. You can leave any question blank, clear the notes or choose not to use it. A file you deliberately download remains on your device and should be stored privately. Share detailed information through an agreed clinical channel rather than an ordinary marketing inquiry. Someone helping with notes should distinguish their observations from your account.
For planned care, a VAYEMA assessment can discuss relevant expertise or referral, and care coordination may help with practical handovers. Actual prescribing and follow-up responsibilities must be clear. Running out of medicine, a sudden change or a serious reaction needs timely direct advice from the responsible clinician or urgent service. Preparation should make care easier to access, not postpone it.
Frequently asked questions about Z-drug assessment
Does this worksheet diagnose zopiclone addiction?
No. It is an original unscored preparation aid. Physical dependence, addiction, adverse effects and persistent insomnia are separate assessment questions. A clinician needs the medicine history and your current condition. The worksheet does not label you, prescribe a reduction or determine that a particular care setting is safe.
Should I try a night without medication before the review?
Do not change medication to test yourself. Explain previous experiences and ask the responsible prescriber for advice. Planned withdrawal needs an individual approach. Serious medicine-specific adverse reactions may require a different urgent response; follow the actual product’s safety instructions and contact a professional directly.
What if I cannot remember an activity that happened after taking the medicine?
Seek prompt medical advice rather than wait to complete a form. For complex sleep behaviours involving zolpidem, eszopiclone or zaleplon, FDA advice is to stop the medicine and contact a healthcare professional immediately. Possible dependence also needs safe clinical management. Injury or immediate danger requires emergency services.
Do I need an overnight sleep study first?
Not everyone does. The clinician can review the history and decide whether another sleep condition or medical issue needs investigation. An expensive or technical test is not automatically the most useful first step. Ask what a proposed investigation would clarify and how the findings would change treatment.
Can I request help without accepting an addiction label?
Yes. A prescribed-medicine review can address dependence and withdrawal without assuming a substance-use disorder. Be open about actual use and concerns so the professional can assess them appropriately. The purpose is to find suitable support, not make access conditional on a label you have assigned to yourself.
Will the notes be sent to my prescriber?
No. The worksheet does not transmit or monitor what you enter. You decide whether to share a downloaded note through an agreed clinical channel. Do not rely on the tool to report an urgent symptom, request a prescription or arrange an appointment. Contact the appropriate service directly for those needs.
Resources and references
[1] NICE NG215: safe review and withdrawal of medicines
[2] NICE NG215: distinguishing withdrawal from other symptoms
[4] FDA: Z-drug risks and impairment
[5] FDA: complex sleep behaviour warning